Latest & greatest articles for atenolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atenolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atenolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atenolol

1. Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. (Abstract)

Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated. We searched PubMed (Medline), Central, Embase, Web of Science and EBSCOhost (until May 2018) for the eligible studies reporting more than 10 IH patients who (...) were treated with oral atenolol with detailed original data, including outcomes, regimens and adverse events (AEs). The data was standardised and analysed by using R software with meta-package. A total of 9 of 141 identified articles, including 341 infantile haemangioma patients treated with oral atenolol therapy, were included. The pooled response rate of atenolol was 0.90 (95% CI: 0.85-0.93), and the rebound rate was 0.11 (95% CI: 0.08-0.16). Among the 341 patients, 44 patients were switched

2018 Australasian Journal of Dermatology

2. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome (Full text)

Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome Beta-blockers are the standard treatment in Marfan syndrome (MFS). Recent clinical trials with limited follow-up yielded conflicting results on losartan's effectiveness in MFS.The present study aimed to evaluate the benefit of losartan compared with atenolol for the prevention of aortic dilation and complications in Marfan patients over a longer observation period (>5 years).A total of 128 patients (...) included in the previous LOAT (LOsartan vs ATenolol) clinical trial (64 in the atenolol and 64 in the losartan group) were followed up for an open-label extension of the study, with the initial treatment maintained.Mean clinical follow-up was 6.7 ± 1.5 years. A total of 9 events (14.1%) occurred in the losartan group and 12 (18.8%) in the atenolol group. Survival analysis showed no differences in the combined endpoint of need for aortic surgery, aortic dissection, or death (p = 0.462). Aortic root

2018 EvidenceUpdates PubMed abstract

3. Atenolol

Atenolol Top results for atenolol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atenolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

4. A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. (Abstract)

A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. This meta-analysis of randomized parallel controlled trials was designed to compare the efficacy of atenolol with angiotensin-converting enzyme inhibitors (ACEIs) in changing pulse wave velocity (PWV), peripheral blood pressure and heart rate (HR) among patients with essential hypertension.This study was conducted (...) according to the PRISMA guideline. Data collection was independently completed by two investigators. Statistical analyses were completed by Stata software (v12.0).Eight clinical trials were meta-analyzed in this study. Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral systolic blood pressure (PSBP) (WMD = -1.281 mmHg, 95% CI: -6.936 to 4.375, P = 0.657) did not differ significantly between atenolol and ACEIs

2018 Clinical and experimental hypertension (New York, N.Y. : 1993)

6. Comment on Kuyper et al.-Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. (Abstract)

Comment on Kuyper et al.-Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. 25746028 2015 05 11 2018 12 02 1916-7075 31 3 2015 Mar The Canadian journal of cardiology Can J Cardiol Comment on Kuyper et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. 365.e5 10.1016/j.cjca.2014.11.015 S0828-282X(14)01578-5 Li Mingxing M Department of Pharmacy, Zhu Jiang Hospital, Southern Medical University, Guangzhou, China. Jiang (...) : yongwh2005@163.com. eng Letter Comment 2014 11 20 England Can J Cardiol 8510280 0828-282X 0 Adrenergic beta-Antagonists 0 Calcium Channel Blockers 50VV3VW0TI Atenolol IM Can J Cardiol. 2014 May;30(5 Suppl):S47-53 24750981 Can J Cardiol. 2015 Mar;31(3):365.e7-8 25746029 Adrenergic beta-Antagonists administration & dosage Atenolol administration & dosage adverse effects Calcium Channel Blockers administration & dosage Humans Hypertension drug therapy Stroke etiology 2014 11 16 2014 11 18 2014 11 18 2015 3

2015 The Canadian journal of cardiology

7. Reply to Letter From Li et al.-Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. (Abstract)

Reply to Letter From Li et al.-Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. 25746029 2015 05 11 2018 12 02 1916-7075 31 3 2015 Mar The Canadian journal of cardiology Can J Cardiol Reply to letter from Li et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. 365.e7-8 10.1016/j.cjca.2015.01.005 S0828-282X(15)00030-6 Kuyper Laura L Khan Nadia A NA eng Letter Comment 2015 01 15 England Can J Cardiol 8510280 0828 (...) -282X 0 Adrenergic beta-Antagonists 0 Calcium Channel Blockers 50VV3VW0TI Atenolol IM Can J Cardiol. 2014 May;30(5 Suppl):S47-53 24750981 Can J Cardiol. 2015 Mar;31(3):365.e5 25746028 Adrenergic beta-Antagonists administration & dosage Atenolol administration & dosage adverse effects Calcium Channel Blockers administration & dosage Humans Hypertension drug therapy Stroke etiology 2015 01 13 2015 01 13 2015 01 13 2015 3 10 6 0 2015 3 10 6 0 2015 5 12 6 0 ppublish 25746029 S0828-282X(15)00030-6

2015 The Canadian journal of cardiology

8. Atenolol versus losartan in children and young adults with Marfan's syndrome. (Full text)

Atenolol versus losartan in children and young adults with Marfan's syndrome. Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate of aortic-root enlargement (...) months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero, indicating a decrease in the aortic-root

2014 NEJM Controlled trial quality: predicted high PubMed abstract

9. Atenolol

Atenolol USE OF ATENOLOL IN PREGNANCY 0344 892 0909 USE OF ATENOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Atenolol is a cardioselective (beta1 selective) beta-adrenoceptor blocking (...) drug (beta-blocker) licensed for the treatment of hypertension, angina pectoris, cardiac dysrhythmia, and for early intervention in the acute phase of myocardial infarction. Data on overall rates of fetal structural malformations, or of specific malformations following first trimester use of atenolol, are too limited to permit an evidence-based risk assessment. There are also insufficient data to assess the risk of spontaneous abortion, stillbirth and adverse neurodevelopmental outcomes following

2014 UK Teratology Information Service

10. Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. (Full text)

Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We sought to compare the efficacy of atenolol vs nonatenolol β-blockers in clinical trials enrolling young (< 60 years) and older patients (...) with hypertension.The Cochrane and MEDLINE databases were searched (January 2006-May 2013) for randomized trials evaluating stroke, myocardial infarction, death, or composite cardiovascular end points. Twenty-one hypertension trials with data on 145,811 participants were identified: 15 used atenolol, 7 were placebo-controlled trials, and 14 were active comparator trials. There were no trials of newer generation β-blockers identified.Among the elderly, atenolol was associated with an increased risk of stroke

2014 The Canadian journal of cardiology PubMed abstract

11. Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) (Abstract)

Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct (...) -comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF. Compared to β(1)-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644

2013 EvidenceUpdates

12. Effect of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients (Abstract)

Effect of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients To assess whether reduction of heart rate (HR) has beneficial effects on endothelial function in patients with type 2 diabetes mellitus (T2DM).Randomised, double-blind, placebo-controlled study.University hospital.66 T2DM patients without overt cardiovascular disease.Patients were randomised to receive for 4 weeks, in addition to their standard therapy, one of the following (...) treatments: atenolol (25 mg twice daily), ivabradine (5 mg twice daily) or placebo (1 tablet twice daily).Systemic endothelial function, assessed by flow-mediated dilation (FMD); endothelium-independent vasodilation, assessed by nitrate-mediated dilation (NMD); cardiac autonomic function, assessed by HR variability (HRV).61 patients completed the study (19, 22 and 20 patients in atenolol, ivabradine and placebo groups, respectively). Compared with baseline, HR was similarly reduced by atenolol (87±13 vs

2012 EvidenceUpdates Controlled trial quality: predicted high

13. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared (...) with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, Anglo-Scandinavian Cardiac Outcomes Trial investigators Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2009 NHS Economic Evaluation Database.

14. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen (Full text)

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.Primary care.Patients with moderate hypertension and three or more additional risk (...) factors.Amlodipine 5-10 mg with perindopril 4-8 mg added as needed or atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as neededCost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.In the UK, the cost to avoid one cardiovascular event or procedure would be euro18 965, and the cost to gain one quality-adjusted life-year would be euro21 875. The corresponding figures for Sweden were euro13 210 and euro16 856.Compared with the thresholds

2008 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

15. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

16. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? (Abstract)

Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Twelve years after the design of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan- vs atenolol-based therapy for cardiovascular outcomes, we reviewed the literature for the effect of beta-blockers compared with initial placebo or no treatment on reduction of cardiovascular events to re-evaluate atenolol (...) as the comparator in the LIFE study.A literature search was conducted in September 2006 for randomized, controlled trials comparing beta-blockers with/without diuretics with placebo or no treatment in patients with hypertension and without recent cardiovascular morbidity. We calculated risk reductions for combined cardiovascular events, cardiovascular death, stroke, and coronary heart disease from groups of trials using atenolol first-line and all beta-blockers first-line.Five studies met the criteria

2007 Blood pressure

17. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension (Full text)

Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Article Text

2007 Evidence-Based Medicine PubMed abstract

18. Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension (Full text)

Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Article Text Therapeutics Review: atenolol may

2006 Evidence-Based Medicine PubMed abstract

19. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B (Abstract)

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and beta blockers used. For a given reduction in blood pressure, some suggested (...) that newer agents would confer advantages over diuretics and beta blockers. Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril.We did a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors. Patients were assigned either amlodipine 5-10 mg adding perindopril 4-8 mg

2005 Lancet Controlled trial quality: predicted high

20. [Criticism against the atenolol meta-analysis remains]. (Abstract)

[Criticism against the atenolol meta-analysis remains]. 15754686 2005 03 11 2013 11 21 0023-7205 102 6 2005 Feb 7-13 Lakartidningen Lakartidningen [Criticism against the atenolol meta-analysis remains]. 412, 414; discussion 414-5 Forsén Kent K kent.forsen.mma@telia.com swe Journal Article Kritiken mot metaanalysen av atenolol kvarstår. Sweden Lakartidningen 0027707 0023-7205 0 Adrenergic beta-Antagonists 0 Antihypertensive Agents 50VV3VW0TI Atenolol IM Adrenergic beta-Antagonists adverse (...) effects therapeutic use Antihypertensive Agents adverse effects therapeutic use Atenolol adverse effects therapeutic use Humans Hypertension drug therapy Meta-Analysis as Topic 2005 3 10 9 0 2005 3 12 9 0 2005 3 10 9 0 ppublish 15754686

2005 Läkartidningen